Lv1
50 积分 2025-03-14 加入
Clearance of residual genome editing components used for ex vivo genome-editing of allogeneic cell therapy products
2小时前
待确认
Prime Editing for p47 phox -Deficient Chronic Granulomatous Disease
3个月前
已完结
Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trials
4个月前
已完结
CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia
4个月前
已完结
AAV-mediated exon skipping therapy for Usher syndrome, type 2A
5个月前
已完结
CRISPR technology: A decade of genome editing is only the beginning
6个月前
已完结
Genome-editing medicinal products: the EMA perspective
6个月前
已完结
Global burden of sickle cell disease in 2021
7个月前
已完结
A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT)
7个月前
已完结
Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3
9个月前
已完结
皖公网安备34019202002308
